Eric Devroe, Chief Operating Officer of Acrivon Therapeutics, Inc., filed a statement of changes in beneficial ownership on November 19, 2026, disclosing a sale of 628 shares of common stock on November 17, 2026, to cover mandatory tax withholding obligations tied to the vesting of restricted stock units.
Key Highlights
- Reporting person: Eric Devroe, Chief Operating Officer of Acrivon Therapeutics, Inc. (NASDAQ:ACRV)
- Transaction date: November 17, 2026, with the filing submitted November 19, 2026
- Shares disposed: 628 shares of common stock sold at a weighted average price of $1.45 per share
- Purpose: Shares were sold automatically to satisfy mandatory tax withholding upon vesting of restricted stock units
- Beneficial ownership following transaction: 145,721 shares of common stock held directly
- Broker sale scope: The broker sold a total of 4,070 shares on November 17, 2026, on behalf of a group of Acrivon employees, with proceeds allocated on a pro rata basis
Eric Devroe's November 2026 RSU Tax-Withholding Sale at Acrivon Therapeutics
According to the filing, Eric Devroe, who serves as Chief Operating Officer of Acrivon Therapeutics, Inc., disposed of 628 shares of the company's common stock on November 17, 2026. The transaction code reported is "S," indicating a sale. The filing states the shares were "sold automatically to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units," rather than representing a discretionary open-market sale initiated by Devroe independently.
The filing further discloses that the $1.45 per share price reflects a weighted average, as a broker sold a total of 4,070 shares on that date on behalf of a group of Acrivon Therapeutics employees. Proceeds from those combined sales were then allocated to the participating employees, including Devroe, on a pro rata basis. Following the reported transaction, Devroe directly holds 145,721 shares of Acrivon Therapeutics common stock, according to the filing. No derivative securities transactions were reported in Table II of the filing.
Acrivon Therapeutics is a clinical-stage biopharmaceutical company. The filing was signed by Adam D. Levy as Attorney-in-Fact on November 19, 2026.
What Was Disclosed
The filing disclosed that Acrivon Therapeutics COO Eric Devroe disposed of 628 shares of common stock on November 17, 2026, at a weighted average price of $1.45, solely to cover tax withholding upon RSU vesting, leaving him with 145,721 directly held shares.





Please wait processing your request...